Abivax SA (ABVX)
ABVX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ABVX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | 2023 |
| SEC CIK | 0001956827 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | France |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-23 |
| Cash and burn | 516.7M EUR cash; operating cash flow -40.3M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 78,536,412 (2025-12-31); 63,347,837 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-07-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PRICEWATERHOUSECOOPERS AUDIT, NEUILLY-SUR-SEINE, France | PCAOB Form AP 2026-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -336.1M EUR | -161.1M EUR | 516.7M EUR | No debt tags | Needs four quarters | 20-F 2026-03-23 |
| FY 2024 2024-12-31 | Not filed | -176.2M EUR | -154.1M EUR | 144.2M EUR | No debt tags | Needs four quarters | 20-F 2026-03-23 |
| FY 2023 2023-12-31 | Not filed | -147.7M EUR | -97.1M EUR | 251.9M EUR | No debt tags | Needs four quarters | 20-F 2026-03-23 |
| FY 2022 2022-12-31 | Not filed | -60.7M EUR | -53.9M EUR | 26.9M EUR | No debt tags | Needs four quarters | 20-F 2025-03-24 |
| FY 2021 2021-12-31 | Not filed | -42.5M EUR | -45.0M EUR | 60.7M EUR | No debt tags | Needs four quarters | 20-F 2024-04-05 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-02 |
| Latest annual report | 20-F | 2026-03-23 |
| Latest quarterly / interim | 6-K | 2026-09-21 |
Source: SEC EDGAR submissions feed, 106 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.2% |
| 1 month | +1.6% |
| 3 months | -27.9% |
| Year to date | -35.1% |
| 1 year | -13.2% |
| From 52-week high | -39.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
| KNSA | Kiniksa Pharmaceuticals International plc | $94.23 | -2.18% | $7.4B |
| CYTK | Cytokinetics Incorporated | $53.17 | -5.27% | $7.4B |
| RYTM | Rhythm Pharmaceuticals Inc. | $107.48 | -6.56% | $7.5B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| BLTE | Belite Bio Inc | $162.56 | -1.09% | $6.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier